Uncategorized

Foresee Pharmaceuticals Announces First Patient Dosed in the Casppian, Phase 3 Clinical Trial of Leuprolide (FP-001) injectable emulsion, 42 mg for the treatment of Central Precocious Puberty patients.

Foresee Pharmaceuticals, announces that the first patient has been dosed in the Casppian Phase 3 registration study.

Foresee Pharmaceuticals Announces First Patient Dosed in the Casppian, Phase 3 Clinical Trial of Leuprolide (FP-001) injectable emulsion, 42 mg for the treatment of Central Precocious Puberty patients. Read More »

Novotech Announces Key Leadership Appointments: Rick Farris, North America Managing Director and Dr. David Ng, Global Vice President of Biometrics and Data

Novotech, the leading Asia Pacific centred biotech CRO with global execution capabilities, announces significant senior executive hires to further expand services for Novotech’s global biotech clients.

Novotech Announces Key Leadership Appointments: Rick Farris, North America Managing Director and Dr. David Ng, Global Vice President of Biometrics and Data Read More »

Global Registrational Phase III Study of Bcl-2 Inhibitor Lisaftoclax in Treatment-Naïve Patients with CLL/SLL Approved by the China CDE

Ascentage Pharma announced that the Center for Drug Evaluation of China NMPA has approved a global pivotal registrational Phase III study designed to evaluate a key drug candidate in Ascentage Pharma’s pipeline, Bcl-2 inhibitor APG-2575, in combination with the Bruton’s tyrosine kinase inhibitor acalabrutinib.

Global Registrational Phase III Study of Bcl-2 Inhibitor Lisaftoclax in Treatment-Naïve Patients with CLL/SLL Approved by the China CDE Read More »

Scroll to Top